Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab in primary Sjögren's syndrome
ISRCTN65360827Phase 3Completed
- Sponsor
- University of Leeds
- Start
- Jan 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in primary Sjögren's syndrome comparing Rituximab with Placebo (2 arms). Primary endpoint: Composite symptom response. Started Jan 2011; status: completed.
02
Drugs
rituximab
03
Conditions
primary Sjögren's syndrome
Beyond the preview
Go deeper on ISRCTN65360827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN65360827.